ReproNovo
repronovo.com
Women’s Health & Maternity
Health Care
Fertility & IVF
As featured in
Claim pageClaim
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
Funding and backers
Total raised
$65M
1 round on record
Latest round
$65M
Series A · May 2025 · 16 mo ago
Backers
3
Jeito Capital, M Ventures
The money's age
Due for its next round
16 months since the last round · not hiring
Momentum
0/100
no fresh signals
Last sign of life
this month
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Mar 20
Board appointment REPRONOVO APPOINTS MARK ALTMEYER AS CHAIRMAN OF THE BOARD · The Manila Times
May 20, 2025
Raised a round Series A $65M · led by Jeito Capital · Nasdaq
2021
Founded
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Series A | May 2025 | $65M | Jeito Capital lead, M Ventures lead | Nasdaq |
Registers and programsofficial lists and records that name the company
| Legal entity | CHE-198.216.736 TVA ReproNovo ApS | its site |
Founders and leadersfrom filings, registers and the company's site
Jean DuvallChief Executive Officercompany's site
Backed byfrom the funds' portfolios and accelerator catalogs
Jeito Capital 
M Ventures 
Ysios Capital Investors in similar startupsfunds that back the companies most like this one
Similar startupsby what they do, their industry and backers
Today. Tomorrow. Always. Onto Health provides integrative fertility and reproductive health care designed around your goals, your life, and…
Genetico is a Russian centre for genetics and reproductive medicine offering genetic testing. Patients can take genetic tests and consult a…
World-class fertility care with cutting-edge technology. Expert IVF, egg freezing, and reproductive services in Lisbon, Portugal. Book your…
Hertility is a London health company founded in 2020 that provides at-home reproductive hormone testing and clinical follow-up. Its service…
0 At Granata Bio, we believe fertility care should evolve with the needs of today's patients. That's why we focus exclusively on…
Reticular is a reproductive-genetics information service for people planning a pregnancy or using IVF.
News
ReproNovo announces first participant dosed in EU Phase 2 trial of RPN-002 for embryo implantation
ReproNovo, a clinical-stage biopharmaceutical company committed to addressing critical gaps in male and female fertility as well as women's health, today announced that the first participant has been dosed in the Company's EU Phase 2 clinical trial of RPN
Read more
Report
REPRONOVO ANNOUNCES FIRST PARTICIPANT DOSED IN EU PHASE 2 TRIAL OF RPN-002 FOR EMBRYO IMPLANTATION
Lausanne, Switzerland and Copenhagen, Denmark, July 06, 2026 (GLOBE NEWSWIRE) -- REPRONOVO ANNOUNCES FIRST PARTICIPANT DOSED IN EU PHASE 2 TRIAL OF RPN-002 FOR EMBRYO IMPLANTATION RPN-002 is an orally administered oxytocin receptor antagonist aiming to im
Read more
Report
REPRONOVO APPOINTS MARK ALTMEYER AS CHAIRMAN OF THE BOARD
Lausanne, Switzerland and Copenhagen, Denmark, March 20, 2026 (GLOBE NEWSWIRE) -- REPRONOVO APPOINTS MARK ALTMEYER AS CHAIRMAN OF THE BOARD
Read more
Report
ReproNovo: $65 Million Series A Raised For Advancing Reproductive Medicine And Women's Health Therapies
ReproNovo, a company dedicated to developing innovative treatments for reproductive medicine and women's health, announced the successful closing of a $65 million Series A financing round. The funding round was led by Jeito Capital, co-led by AXA IM Alts
Read more
Report
ReproNovo Raises $65 Million Series A Financing to Advance Phase 2 Clinical Trials of Novel Therapies in Reproductive Medicine and Women's Health
Round led by Jeito Capital, co-led by AXA IM Alts and M Ventures, with strong syndicate support from Ysios Capital and ALSA Ventures LAUSANNE, SWITZERLAND AND COPENHAGEN, DENMARK / ACCESS Newswire / May 21, 2025 /ReproNovo , a company dedicated to ...
Read more
Report
Report
ReproNovo Raises $65 Million Series A Financing to Advance Phase 2 Clinical Trials of Novel Therapies in Reproductive Medicine and Women's Health
Round led by Jeito Capital, co-led by AXA IM Alts and M Ventures, with strong syndicate support from Ysios Capital and ALSA Ventures. LAUSANNE, SWITZERLAND AND COPENHAGEN, DENMARK/ ACCESS Newswire/ May 21, 2025/ ReproNovo, a company dedicated to developin
Read more
Report
People
Jean Duvall
Chief Executive Officer
Names and roles come from public filings, company registers and the company's own site. Is this you? Correct or remove · How we handle this data
Financials
Total raised
$65M
Latest round
Series A
Funding rounds
1
Funding rounds
| Round | Announced | Amount | |
|---|---|---|---|
| Series A | 2025 | $65M | Details |